Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kerrie-Anne Heron

Internal Medicine Wilson, NC Medical Doctor

NPI 1518953504 CMS profile 159978

3302 Nash St N, Wilson, NC 27896

Open in the dashboard

General payments

$3,682

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerrie-Anne Heron of Wilson, NC is reported in the CMS Open Payments database as having received $3,682 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $982 56
2024 General $626 36
2023 General $32 1
2022 General $15 1
2021 General $13 1
2020 General $313 21
2019 General $1,702 148

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerrie-Anne Heron
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Kerrie-Anne Heron were reported at $982. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Kerrie-Anne Heron Internal Medicine median Middle half National median
2019 $1,702 $159 $48–$570 $163
2020 $313 $119 $33–$402 $114
2021 $13 $135 $37–$521 $132
2022 $15 $141 $42–$496 $149
2023 $32 $149 $45–$519 $160
2024 $626 $154 $47–$537 $164
2025 $982 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $469 38 payments
  2. AstraZeneca Pharmaceuticals LP $310 20 payments
  3. GlaxoSmithKline, LLC. $289 17 payments
  4. Pfizer Inc. $269 30 payments
  5. AbbVie, Inc. $248 15 payments
  6. Lilly USA, LLC $207 20 payments
  7. Amgen Inc. $175 11 payments
  8. Merck Sharp & Dohme Corporation $171 13 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $164 16 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $151 9 payments
  11. Other $1,229 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,668 262 payments
  2. Education $15 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $293 23 payments
  2. TRELEGY ELLIPTA $247 15 payments
  3. FARXIGA $179 11 payments
  4. XIFAXAN $151 9 payments
  5. RYBELSUS $136 8 payments
  6. Repatha $117 7 payments
  7. UBRELVY $100 8 payments
  8. JANUMET $95 8 payments
  9. JANUMET XR $95 8 payments
  10. JANUVIA $95 8 payments
  11. Other $3,654 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 180 drugs

Part D claims

17,077

Median for Internal Medicine: 777

Drug cost

$1,761,193

Median for Internal Medicine: $73,373

Branded share of claims

24.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 259 $265,922
Jardiance Empagliflozin Brand 186 $153,453
Rybelsus Semaglutide Brand 135 $138,732
Januvia Sitagliptin Phosphate Brand 157 $134,279
Eliquis Apixaban Brand 160 $127,107
Abrysvo Rsv Vacc, Pref A And Pref B/Pf Brand 371 $118,811
Mounjaro Tirzepatide Brand 77 $84,678
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 86 $64,245
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 248 $55,021
Trulicity Dulaglutide Brand 41 $54,124

The 10 drugs with the highest cost, of 180 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$482,255

Of which drugs: $105,270

Medicare patients

989

Average age 74

Services billed

31,540

636 women, 353 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 37%
Arthritis 37%
Osteoporosis 25%
Depression 23%
Chronic kidney disease 22%
Ischemic heart disease 20%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscov2 vac 50 mcg/0.5ml im 91322 Office 205 277 $41,719
Vaccine for influenza for injection into muscle 90653 Office 376 376 $30,756
Sarscv2 vac 30mcg trs-suc im 91320 Office 115 164 $23,081
Pcv20 vaccine im 90677 Office 21 21 $6,124
Influenza vaccine, trivalent derived from cell cultures 90661 Office 25 25 $831
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 62 380 $249
Injection, zoledronic acid, 1 mg J3489 Office 19 51 $195
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 44 221 $182

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $39
$39 18 —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $38
$38 — —
RYBELSUS
  • Novo Nordisk Inc $36
$36 135 —
Ozempic
  • Novo Nordisk Inc $36
$36 259 —
Leqembi
  • Eisai Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record